Tocilizumab
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tocilizumab is a humanized monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptor and inhibits IL-6R-mediated signaling.
“TCZ, a humanized mAb, binds to both soluble and membrane-bound IL-6R and inhibits IL-6R-mediated signaling.96”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [96]
Cites
Smolen, J. S., Beaulieu, A. D., Rubbert‐Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., WOODWORTH, T. G., & Alten, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60453-5 · Cited by 1,399 · see citing works
Self-citationEmery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104 · see citing works
New therapies for treatment of rheumatoid arthritis
Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H., & Emery, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60784-3 · Cited by 983 · see citing works
Self-citationGenovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855 · see citing works
Interleukin 6: from bench to bedside
Nishimoto, N., & Kishimoto, T. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0338 · Cited by 639 · see citing works
Interleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604 · see citing works
Madhok, R., Crilly, A., Watson, J., & Capell, H. A. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.3.232 · Cited by 340 · see citing works
Mackay, K., Mack, C., Brophy, S. T., & Călin, A. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12 · Cited by 327 · see citing works
Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato, K., Tsuchiya, M., Saldanha, J. W., Koishihara, Y., Ohsugi, Y., Kishimoto, T., & Bendig, M. M. (1993) · PubMed · Cited by 274 · see citing works
Smolen, J. S., Han, C., van der Heijde, D. M. F. M., Emery, P., Bathon, J. M., Keystone, E., Maini, R. N., Kalden, J. R., Aletaha, D., Baker, D., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.090019 · Cited by 236 · see citing works
Self-citationAssessing remission in clinical practice
Mierau, M., Schoels, M., Gonda, G., Fuchs, J., Aletaha, D., & Smolen, J. S. (2007) · Rheumatology · doi:10.1093/rheumatology/kem007 · Cited by 197 · see citing works
Self-citationInterleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis
Sack, U., Kinne, R. W., Marx, T., Heppt, P., Bender, S., & Emmrich, F. (1993) · Rheumatology International · doi:10.1007/bf00307733 · Cited by 126 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Franceschi, C., Garagnani, P., Vitale, G., Capri, M., & Salvioli, S. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.09.005 · Cited by 997 · see citing works
Biopharmaceutical benchmarks 2010
Walsh, G. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-917 · Cited by 755 · see citing works
Aliyu, M., Zohora, F. T., Anka, A. U., Ali, K., Maleknia, S., Saffarioun, M., & Azizi, G. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109130 · Cited by 433 · see citing works
Bevaart, L., Vervoordeldonk, M. J., & Tak, P. P. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27503 · Cited by 254 · see citing works
Caetano, M. S., Zhang, H., Cumpian, A. M., Gong, L., Ünver, N., Ostrin, E. J., Daliri, S., Chang, S. H., Ochoa, C. E., Hanash, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2840 · Cited by 227 · see citing works
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor
Clark, P. G. K., Vieira, L. C. C., Tallant, C., Fedorov, O., Singleton, D. C., Rogers, C. M., Monteiro, O., Bennett, J. M., Baronio, R., Müller, S., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201501394 · Cited by 167 · see citing works
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor
Clark, P. G. K., Vieira, L. C. C., Tallant, C., Fedorov, O., Singleton, D. C., Rogers, C. M., Monteiro, O., Bennett, J. M., Baronio, R., Müller, S., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201501394 · Cited by 123 · see citing works
Rheumatoid Arthritis: A Role for Immunosenescence?
Lindström, T. M., & Robinson, W. H. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02965.x · Cited by 122 · see citing works
Venkiteshwaran, A. (2009) · mAbs · doi:10.4161/mabs.1.5.9497 · Cited by 114 · see citing works
Jose, S. S., Bendíčková, K., Kepák, T., Křenová, Z., & Frič, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01078 · Cited by 105 · see citing works
A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130
Hong, S., Choi, J. H., Lee, S. Y., Park, Y.-H., Park, K.-Y., Lee, J. Y., Kim, J., Gajulapati, V., Goo, J.-I., Singh, S., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402908 · Cited by 101 · see citing works
Hohki, S., Ohguro, N., Haruta, H., Nakai, K., Terabe, F., Serada, S., Fujimoto, M., Nomura, S., Kawahata, H., Kishimoto, T., et al. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.04.009 · Cited by 92 · see citing works
Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines
Schmitz, M. L., Weber, A., Roxlau, T., Gaestel, M., & Kracht, M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.06.019 · Cited by 92 · see citing works
Tocilizumab for the treatment of rheumatoid arthritis
Tanaka, T., Ogata, A., & Narazaki, M. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.70 · Cited by 99 · see citing works
Advances in the Discovery of Selective JAK Inhibitors
Menet, C. J., Rompaey, L. V., & Geney, R. (2013) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-62652-3.00004-1 · Cited by 80 · see citing works
Genome-wide association study of circulating interleukin 6 levels identifies novel loci
Ahluwalia, T. S., Prins, B. P., Abdollahi, M., Armstrong, N. J., Aslibekyan, S. W., Bain, L., Jefferis, B. J. M. H., Baumert, J. J., Beekman, M., Ben‐Shlomo, Y., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab023 · Cited by 53 · see citing works
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24850 · Cited by 51 · see citing works
Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects
Brod, S. A. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102538 · Cited by 48 · see citing works
IL-6 activates STAT5 in T cells.
Tormo, A., Letellier, M., Sharma, M., Elson, G., Crabé, S., & Gauchat, J. (2012) · Cytokine · doi:10.1016/j.cyto.2012.07.002 · Cited by 45 · see citing works
Tormo, A. J., Meliani, Y., Beaupré, L. A., Sharma, M., Fritz, J. H., Elson, G., Crabé, S., & Gauchat, J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201595 · Cited by 42 · see citing works
Pizzi, M., Boi, M., Bertoni, F., & Inghirami, G. (2016) · Leukemia · doi:10.1038/leu.2016.161 · Cited by 38 · see citing works
Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations
Hall, V. G., Johnson, D. F., & Torresi, J. (2018) · Journal of Travel Medicine · doi:10.1093/jtm/tay018 · Cited by 36 · see citing works
Drug treatment of coronavirus disease 2019 (COVID-19) in China.
Jin, Z., Liu, J.-Y., Feng, R., Ji, L., Jin, Z.-L., & Li, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173326 · Cited by 29 · see citing works
Mahroum, N., Watad, ., Bridgewood, C., Mansour, M., Nasr, A., Hussein, A., Khamisy‐Farah, R., Farah, R. E., Gendelman, O., Lidar, M., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179149 · Cited by 28 · see citing works
Tocilizumab for the treatment of giant cell arteritis
Schirmer, M., Muratore, F., & Salvarani, C. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1468251 · Cited by 26 · see citing works
Lee, J. S., Wang, J., Martin, M., Germer, S., Kenwright, A., Benayed, R., Spleiss, O., Platt, A., Pilson, R., Hemmings, A., et al. (2011) · Pharmacogenetics & Genomics · doi:10.1097/fpc.0b013e32834592fe · Cited by 23 · see citing works
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1
Hurley, C. A., Blair, W. S., Bull, R. J., Chang, C., Crackett, P. H., Deshmukh, G., Dyke, H. J., Fong, R., Ghilardi, N., Gibbons, P., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.018 · Cited by 19 · see citing works
The "Cytokine for Gerontologists" Has Some Company
Roubenoff, R. (2013) · The Journals of Gerontology Series A · doi:10.1093/gerona/glt184 · Cited by 19 · see citing works
Tormo, A. J., Letellier, M.-C., Lissilaa, R., Batraville, L.-A., Sharma, M., Ferlin, W. G., Elson, G., Crabé, S., & Gauchat, J. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.014 · Cited by 17 · see citing works
Antibody drug conjugates beyond cytotoxic payloads
Hobson, A. D. (2023) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2023.10.001 · Cited by 15 · see citing works
Development of triarylsulfonamides as novel anti-inflammatory agents
Greig, I. R., Coste, E., Ralston, S. H., & Hof, R. V. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.067 · Cited by 15 · see citing works
Ingested (oral) tocilizumab inhibits EAE
Brod, S. A., & Bauer, V. L. (2014) · Cytokine · doi:10.1016/j.cyto.2014.04.003 · Cited by 14 · see citing works
Target Identification Using Chemical Probes
Moustakim, M., Felce, S. L., Zaarour, N., Farnie, G., McCann, F. E., & Brennan, P. E. (2018) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2018.09.013 · Cited by 12 · see citing works
Development of small-molecule therapies for autoimmune diseases
Bürli, R. W., Haughan, A. F., & Hodges, A. J. (2010) · Autoimmunity · doi:10.3109/08916931003674758 · Cited by 10 · see citing works
Ma, X., Gao, H., Ge, H., Zhang, Q., & Bu, B. (2024) · Lara D. Veeken · doi:10.1093/rheumatology/keae118 · Cited by 9 · see citing works
Novel agents in the future: Therapy beyond anti‐TNF agents in inflammatory bowel disease
Peng, J. C., Shen, J., & Ran, Z. H. (2014) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12193 · Cited by 8 · see citing works
Cumming, J. G., Debreczeni, J. E., Edfeldt, F., Evertsson, E., Harrison, M., Holdgate, G. A., James, M. J., Lamont, S. G., Oldham, K., Sullivan, J. E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501038s · Cited by 8 · see citing works
Erythroid progenitor cell modulates cancer immunity: Insights and implications
Mo, W., Huang, C., & Sun, Z. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189209 · Cited by 6 · see citing works
Ghazvini, K., Karbalaei, M., & Keikha, M. (2020) · Le Pharmacien Hospitalier et Clinicien · doi:10.1016/j.phclin.2020.11.003 · Cited by 6 · see citing works
Negi, V., Gavlock, D. C., Miedel, M. T., Lee, J. K., Shun, T., Gough, A., Vernetti, L. A., Stern, A. M., Taylor, D. L., & Yechoor, V. K. (2023) · Lab on a Chip · doi:10.1039/d3lc00285c · Cited by 5 · see citing works
BMS acquires rights for IL-6 inhibitor
(2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3094 · Cited by 4 · see citing works
Hurdles and Leaps for Protein Therapeutics
Kozlowski, S., Cherney, B., & Donnelly, R. P. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05158.x · Cited by 3 · see citing works
O’Shea, J. J., Gadina, M., Siegel, R. M., & Farber, J. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00013-9 · Cited by 3 · see citing works
O’Shea, J. J., Sims, J., Siegel, R. M., & Farber, J. M. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00011-7 · Cited by 1 · see citing works
Anti‐Inflammatory and Immunomodulatory Drugs
Edmunds, J. J. (2013) · Drug Discovery · doi:10.1002/9781118354483.ch9 · Cited by 1 · see citing works
Tehrani, R., Ostrowski, R., Hariman, R., & Jay, W. (2009) · Neuro-Ophthalmology · doi:10.3109/01658100903360064 · Cited by 1 · see citing works
Govil, G., Tomar, L., & Dhawan, P. (2022) · IP International Journal of Orthopaedic Rheumatology · doi:10.18231/j.ijor.2021.015
Wang, Y., Wang, Y., Wu, R., Luo, H., Li, Y., Chen, X., Liu, K., Dong, Z., & Liu, H. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102096 · Cited by 1 · see citing works
BindingDB Entry 50043069: Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.
BindingDB (2014) · UC San Diego · doi:10.7270/q2gh9kb2
BindingDB (2021) · UC San Diego · doi:10.7270/q20r9t0j
- Authors
- Scheinecker, C., Smolen, J., Yasothan, U., Stoll, J., & Kirkpatrick, P.
- Affiliations
- Medical University of Vienna (AT)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-04
- Volume
- 8
- Issue
- 4
- Pages
- 273-274
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4233306032
- Cited by
- 49
- References
- 12
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 4 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 3 · 2013: 6 · 2012: 3
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Keywords
- tocilizumab, IL-6 receptor, humanized monoclonal antibody, rheumatoid arthritis, drug approval
- MeSH terms
- Antibodies, Monoclonal, Arthritis, Rheumatoid, Humans, Randomized Controlled Trials as Topic, Receptors, Interleukin-6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
